Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Price Target of $42.33 According to Analysts

Sionna Therapeutics, Inc. (NASDAQ:SION) has been given an average recommendation of “Hold” by the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $42.33.

A number of research analysts have issued reports on the stock. Lifesci Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Wall Street Zen downgraded shares of Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price target for the company in a research note on Monday, August 10th. BTIG Research cut Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. Finally, Citigroup downgraded Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. sold 3,448,811 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $6.33, for a total transaction of $21,830,973.63. Following the completion of the sale, the director directly owned 3,448,812 shares in the company, valued at approximately $21,830,979.96. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SION. BlackRock Inc. acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at approximately $64,875,000. Candriam S.C.A. bought a new stake in shares of Sionna Therapeutics during the 1st quarter worth approximately $9,494,000. Stempoint Capital LP acquired a new stake in shares of Sionna Therapeutics during the 1st quarter worth approximately $1,465,000. Walleye Capital LLC acquired a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $4,282,000. Finally, Jennison Associates LLC increased its stake in Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after acquiring an additional 335,942 shares during the last quarter.

Sionna Therapeutics Stock Performance

SION stock opened at $3.28 on Monday. The company’s 50-day simple moving average is $5.21 and its 200 day simple moving average is $29.21. Sionna Therapeutics has a 52 week low of $3.19 and a 52 week high of $54.97. The company has a market capitalization of $148.29 million, a PE ratio of -1.50 and a beta of 1.23.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, analysts forecast that Sionna Therapeutics will post -2.54 EPS for the current year.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. The company is working to address the underlying cause of CF by developing small-molecule therapies designed to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Sionna’s research centers on the nucleotide-binding domain 1 (NBD1) of CFTR, which plays an important role in the protein’s structure and activity.